This study compared the effectiveness of two chemotherapy regimens, BEACOPP and COPP-ABVD, for treating advanced Hodgkin's lymphoma. 49 patients received either BEACOPP (25 patients) or COPP-ABVD (24 patients). The rate of freedom from treatment failure at 5 years was higher for BEACOPP at 76% compared to 69% for COPP-ABVD. Overall survival rates at 5 years were also higher for BEACOPP at 88% versus 83% for COPP-ABVD. While BEACOPP resulted in better tumor control and survival, it also had more acute toxicity including grade 4 leukopenia in some cycles.

1. Standard BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease Moscow State University Faculty of Fundamental Medicine N.N.Blokhin Cancer Research Center Presented By : Dr .Sa Thi Ha (M.B;B.S) Supervisor : Prof Dr.B.I.Polyakov Dr.D.A.Bykov 17 th may 2010

3. Reed-Sternberg cell

14. 55 patients recruited 28 Assigned to BEACOPP 27 Assigned to COPP-ABVD 2 Excluded 2 did not have Hodgkin’s disease 2 Excluded 2 did not have Hodgkin’s disease 26 Eligible 1 lost to follow up 25 Elgible 1 lost to follow up 25 Included in the analysis 23 received full course 2 received partial course 24 Included in the analysis 20 received full course 4 received partial course Numbers of patients included in this analysis

15. Characteristics of patients

16. Chacteristics of patients by stage

17. Acute Adverse Effects of Chemotherapy

18. Kaplan–Meier Analysis of the Probability of Freedom from Treatment Failure (Panel A) and Overall Survival (Panel B)

19. Rate of the early progression and Five year Kaplain-Meier estimates of the rate of free from treatment failure according to the International Prognostic Index. International Prognostic Index COPP-ABVD (%) Standard BEACOPP(%) Early progression Good (0-1) Fair (2-3) Poor (4-7) Freedom from treatment failure at 5 years Good (0-1) Fair (2-3) Poor (4-7) Overall survival at 5 years Good (0-1) Fair (2-3) Poor (4-7) 10 11 18 79 67 59 92 84 67 6 9 9 81 72 74 93 86 81

20. Outcome of Treatment and Five-Year Survival Rates. Variable COPP-ABVD (N=24) Standard BEACOPP (N=25) percent Complete remission 85(80-89) 88(85-91) Early progression 10(7-15) 8(5-10) Freedom from treatment failure at 5 yr 69(63-75) 76(72-80) Overall survival at 5 yr 83(78-87) 88(85-91)

23. Thank you for attention